Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis.
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis.
复制标题
血小板与淋巴细胞比率在非小细胞肺癌中的预后价值：系统评价和荟萃分析
DOI：
10.1038/srep22618
复制
发表时间：
2016-03-04
影响因子：
4.6
通讯作者：
Wang C
中科院分区：
文献类型：
--
作者：
Zhang H;Gao L;Zhang B;Zhang L;Wang C
血小板/淋巴细胞比率(PLR)在非小细胞肺癌(NSCLC)中的预后价值仍存在争议。因此，我们对已发表的研究进行了荟萃分析，以确定PLR在非小细胞肺癌中的预后价值。应用计算机检索PubMed、Web of Science、Embase等相关研究。提取每项研究的数据和特征，并计算95%可信区间(CI)下的危险比(HR)以评估效果。我们还进行了子组和Meta回归分析。在这项荟萃分析中，共有12项研究中的2,889名患者参加，合并后的HR为1.492(95%CI：1.231-1.807，P <； 0.001)，表明PLR升高的患者在治疗后总生存期(OS)预期较短。这一荟萃分析表明，高PLR可能是NSCLC预后不良的预测因素。需要进一步的大规模队列研究来证实这些发现。
The prognostic value of the platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) remains controversial. We therefore conducted a meta-analysis of published studies to determine the prognostic value of PLR in NSCLC. A systematic search was performed in PubMed, Web of Science and Embase for relevant studies. The data and characteristics of each study were extracted, and the hazard ratio (HR) at a 95% confidence interval (CI) was calculated to estimate the effect. We also performed subgroup and meta-regression analyses. A total of 2,889 patients in 12 studies were enrolled in this meta-analysis, and the pooled HR of 1.492 (95% CI: 1.231–1.807, P < 0.001) indicated that patients with an elevated PLR are expected to have a shorter overall survival (OS) after treatment. This meta-analysis indicates that a high PLR might be a predictive factor of poor prognosis in NSCLC. Further large-cohort studies are needed to confirm these findings.